TY - JOUR
AU - Cruz, Pedro M. Rodríguez
AU - Lam, Jie Min
AU - Abdalla, Jehad
AU - Bell, Samira
AU - Bytyci, Jola
AU - Brosh-Nissimov, Tal
AU - Gill, John
AU - Haidar, Ghady
AU - Hoerger, Michael
AU - Maor, Yasmin
AU - Pagliuca, Antonio
AU - Raff, Francois
AU - Samuels, Ffion
AU - Segev, Dorry
AU - Ying, Yuxin
AU - Lee, Lennard Y.W.
PY - 2024
DA - December
TI - Immunobridging trials: an important tool to protect vulnerable and immunocompromised patients against evolving pathogens
JO - Vaccines
VL - 13
IS - 1
DO - https://doi.org/10.3390/vaccines13010019
AB - Safeguarding patients from emerging infectious diseases demands strategies that prioritise patient well-being and protection. Immunobridging is an established trial methodology which has been increasingly employed to ensure patient protection and provide clinicians with swift access to vaccines. It uses immunological markers to infer the effectiveness of a new drug through a surrogate measure of efficacy. Recently, this method has also been employed to authorise novel drugs, such as COVID-19 vaccines, and this article explores the concepts behind immunobridging trials, their advantages, issues, and significance in the context of COVID-19 and other infectious diseases. Our goal is to improve awareness among clinicians, patient groups, regulators, and health leaders of the opportunities and issues of immunobridging, so that fewer patients are left without protection from infectious diseases, particularly from major pathogens that may emerge.
PB - MDPI
UR - https://discovery.dundee.ac.uk/en/publications/4bec11f5-7e55-438c-9361-c2a46c0a8ba5
KW - Coronavirus (COVID-19)
ER